Trials / Completed
CompletedNCT02463032
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- GTx · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced Estrogen Receptor (ER)+ and Androgen Receptor (AR)+ breast cancer in postmenopausal women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GTx-024 | To determine whether either or both doses result in an acceptable clinical benefit rate. |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2019-03-01
- Completion
- 2019-03-01
- First posted
- 2015-06-04
- Last updated
- 2020-12-09
- Results posted
- 2020-12-09
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02463032. Inclusion in this directory is not an endorsement.